New drug cocktail shows promise in preventing transplant complications
NCT ID NCT03945591
First seen Apr 29, 2026 · Last updated Jun 11, 2026 · Updated 9 times
Summary
This study tested whether a combination of two drugs, cyclophosphamide and bortezomib (CyBor), could prevent graft-versus-host disease (GVHD) in 23 adults with blood cancers who received a stem cell transplant. GVHD is a serious condition where donor cells attack the patient's body. Participants received the drug combo shortly after transplant. The goal was to see if this approach could lower rates of acute and chronic GVHD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York University School of Medicine
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.